

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

- 1-59. (Cancelled).
60. (currently amended): A method according to claim ~~57~~89 in which the solvent is organic and which additionally comprises, following step b), a step:
- c) drying the treated implant to remove the solvent.
61. (previously presented): A method according to claim 60 in which the removal is by evaporation.
62. (currently amended): A method according to claim ~~57~~89 in which the implant is a stent.
63. (previously presented): A method according to claim 62 in which the stent is mounted on a delivery device prior to said contacting step b).
64. (currently amended): A method according to claim ~~57~~89 in which step a) comprises the sub-steps:
- a i) providing an uncoated implant;
- a ii) coating the implant with a cross-linkable polymer; and
- a iii) cross-linking the cross-linkable polymer to form the ~~said~~ cross-linked water-swellaable polymer matrix.
65. (previously presented): A method according to claim 64 in which the cross-linkable polymer is formed from ethylenically unsaturated monomers including
- a) a zwitterionic monomer of the formula I

YBX


I

wherein B is a bond or a straight or branched alkylene, alkylene-oxa-alkylene or alkylene-oligooxa-alkylene group, any of which optionally include one or more fluorine substituents;

X is an organic group having a zwitterionic moiety; and

Y is an ethylenically unsaturated polymerisable group;

b) a cationic monomer of the formula II




II

wherein B¹ is a bond or a straight or branched alkylene, alkylene-oxa-alkylene or alkylene-oligooxa-alkylene group, any of which optionally includes one or more fluorine substituents;

Y¹ is an ethylenically unsaturated polymerisable group, and

Q is an organic group having a cationic or cationisable moiety and

c) a crosslinkable monomer having the general formula IV:



IV


wherein B³ is a bond or a straight or branched alkylene, alkylene-oxa-alkylene or alkylene-oligooxa-alkylene group, any of which optionally includes one or more fluorine substituents;

Y³ is an ethylenically unsaturated polymerisable group; and

Q³ is an organic group having a reactive group capable of cross-linking the polymer.

66. (previously presented): A method according to claim 65 in which Q³ is a group SiR⁴₃ in which R⁴ is a C₁₋₄ alkoxy group or a halogen atom.

67. (previously presented): A method according to claim 65 in which X is a group of formula VI



where the groups R^8 are the same or different and each is hydrogen or C_{1-4} alkyl, and e is from 1 to 6.

68. (previously presented): A method according to claim 65 in which Q^1 is selected from the group consisting of N^+R^5_3 , P^+R^5_3 and S^+R^5_2

in which the groups R^5 are the same or different and are each selected from the group consisting of hydrogen, C_{1-4} -alkyl and aryl, or two of the groups R^5 together with the heteroatom to which they are attached form a saturated or unsaturated heterocyclic ring containing from 5 to 7 atoms.

69. (previously presented): A method according to claim 65 in which the groups Y, Y^1 and Y^3 all have the general formula $\text{CH}_2=\text{C(R)C(O)A-}$ in which A is -O- or $-\text{NR}^1$ where R^1 is hydrogen or a C_{1-4} alkyl group, and R is hydrogen or a C_{1-4} alkyl group.

70-72. (canceled).

73. (currently amended): A method according to claim ~~70~~77 in which the solvent is organic and which additionally comprises, following step b), a step:

c) drying the treated implant to remove the solvent.

74. (previously presented): A method according to claim 73 in which the removal is by evaporation.

75. (currently amended): A method according to claim ~~70~~77 in which the implant is a stent.

76. (previously presented): A method according to claim 75 in which the stent is mounted on a delivery device prior to said contacting step b).

77. (currently amended): A method of producing an implant loaded with a pharmaceutical active comprising the steps:

a) providing a coated implant having a coating of cross-linked water-swella-
ble polymer matrix on its external surface, the cross-linked water-swella-
ble polymer matrix comprising a polymer having pendant zwitterionic groups and pendant cationic groups; and

b) contacting the coated implant with a solution or dispersion of a pharmaceutical
active which is a protein in an aqueous solvent, the protein being anionically charged at
physiological pH, whereby the solvent partially swells the polymer matrix and the
pharmaceutical active is absorbed into or adsorbed onto the polymer matrix,

wherein A method according to claim 70 in which step a) comprises the sub-steps:

a i) providing an uncoated implant;

a ii) coating the implant with a cross-linkable polymer; and

a iii) cross-linking the cross-linkable polymer to form the ~~said~~ cross-linked

water-swella-ble polymer matrix.

78. (previously presented): A method according to claim 77 in which the cross-
linkable polymer is formed from ethylenically unsaturated monomers including

a) a zwitterionic monomer of the formula I

YBX

I

wherein B is a bond or a straight or branched alkylene, alkylene-oxa-alkylene or alkylene-oligooxa-alkylene group, any of which optionally include one or more fluorine substituents;

X is an organic group having a zwitterionic moiety; and

Y is an ethylenically unsaturated polymerisable group;

b) a cationic monomer of the formula II



wherein B¹ is a bond or a straight or branched alkylene, alkylene-oxa-alkylene or alkylene-oligooxa-alkylene group, any of which optionally includes one or more fluorine substituents;

Y¹ is an ethylenically unsaturated polymerisable group, and

Q is an organic group having a cationic or cationisable moiety and

c) a crosslinkable monomer having the general formula IV:




wherein B³ is a bond or a straight or branched alkylene, alkylene-oxa-alkylene or alkylene-oligooxa-alkylene group any of which optionally includes one or more fluorine substituents;

Y³ is an ethylenically unsaturated polymerisable group; and

Q³ is an organic group having a reactive group capable of cross-linking the polymer.

79. (previously presented): A method according to claim 78 in which Q³ is a group SiR⁴₃ in which each R⁴ is a C₁₋₄ alkoxy group or a halogen atom.

80. (previously presented): A method according to claim 78 in which X is a group of formula VI



where the groups R^8 are the same or different and each is hydrogen or C_{1-4} alkyl, and e is from 1 to 6.

81. (previously presented): A method according to claim 78 in which Q^1 is selected from the group consisting of $N^+R^5_3$, $P^+R^5_3$ and $S^+R^5_2$

in which the groups R^5 are the same or different and are each selected from the group consisting of hydrogen, C_{1-4} -alkyl and aryl, or two of the groups R^5 together with the heteroatom to which they are attached form a saturated or unsaturated heterocyclic ring containing from 5 to 7 atoms.

82. (previously presented): A method according to claim 78 in which the groups Y , Y^1 and Y^3 all have the general formula $CH_2=C(R)C(O)A$ - in which A is $-O-$ or $-NR^1$ where R^1 is hydrogen or a C_{1-4} alkyl group, and R is hydrogen or a C_{1-4} alkyl group.

83. (currently amended): A method according to claim ~~70-77~~ in which the protein is an antibody or a fragment thereof.

84. (canceled).

85. (currently amended): A method according to claim ~~57-89~~ in which the nucleic acid is DNA or RNA.

86. (currently amended): A method according to claim ~~57-89~~ in which the nucleic acid has a molecular weight higher than 1kD.

87. (previously presented): A method according to claim 86 in which the nucleic acid has a molecular weight higher than 1.2kD.

88. (previously presented): A method according to claim 85 in which the nucleic acid is linear or circular and is single or double stranded.

89. (currently amended): A method of producing an implant loaded with a pharmaceutical active comprising the steps:

a) providing a coated implant having a coating of cross-linked water-swella-
ble polymer matrix on its external surface, the cross-linked water-swella-
ble polymer matrix comprising a polymer having pendant zwitterionic groups and pendant cationic groups; and

b) contacting the coated implant with a solution or dispersion of a pharmaceutical
active which is a nucleic acid, in an aqueous solvent whereby the solvent partially swells the
polymer matrix and the pharmaceutical active is absorbed into or adsorbed onto the polymer
matrix,

wherein ~~A method according to claim 57 in which~~ the step b) of contacting the coated
implant involves dipping the implant into a volume of the ~~said~~ solution or dispersion.

90. (currently amended): A method according to claim ~~70~~ 77 in which the step b) of
contacting the coated implant involves dipping the implant into a volume of the ~~said~~ solution or
dispersion.

91. (canceled).

92. (canceled).